A 40mg vial of lyophilized retatrutide for laboratory research.
Retatrutide is a triple-action peptide that targets GLP-1, GIP, and glucagon metabolic receptors, supporting astonishing fat loss, improved insulin sensitivity, and enhanced metabolic health.
-
GLP-1 (Glucagon-Like Peptide-1) → Enhances insulin secretion, suppresses appetite, delays gastric emptying
-
GIP (Glucose-Dependent Insulinotropic Polypeptide) → Boosts insulin response, improves insulin sensitivity, may support lipid metabolism
-
Glucagon Receptor (GCGR) → Elevates energy expenditure, promotes fat oxidation, and may reduce liver fat
Recent Clinical trial
The TRIUMPH-1 milestone refers to the highly successful Phase 3 clinical trial results for retatrutide. It achieved historically unprecedented weight loss, at an average of 70.3 lbs (28.3%) of body weight over 80 weeks, at a dosage of 12mg per week. 45.3% of participants achieved ≥30% weight loss, a level long associated with bariatric surgery. See the latest clinical study design paper (October 2025) and the trial results (May 2026).
Our vials are sealed in an ISO 5 clean room under a positive pressure laminar flow hood.
Testing by a third-party using HPLC methods was verified at >99% purity. See our test results.